Menu
Close
Global
×

Company News

Company News
Company News
2025-01-13
ImmuneOnco IMM2510 Combined with Chemotherapy for First-Line NSCLC Treatment Completes Enrollment of First Patient in Phase Ib/II Clinical Trial
On January 13, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco", Stock Code: 01541.HK) announced that the Phase Ib/II clinical trial of its PD-L1xVEGF bispecific antibody IMM2510 combined with chemotherapy for the treatment of first-line non-small cell lung cancer (NSCLC) has completed the enrollment of its first patient. This marks another significant milestone in the rapid clinical advancement of IMM2510.
View more
2024-11-13
The Phase II clinical trial of IMM27M for estrogen receptor positive (ER+) advanced breast cancer that failed after endocrine therapy or recurred and has enrolled the first patient
The board (the “Board”) of directors (“Directors”, and each a “Director”) of the Company is pleased to announce that the Company has initiated the Phase II clinical trial of IMM27M for estrogen receptor positive (ER+) advanced breast cancer that failed after endocrine therapy or recurred and has enrolled the first patient.
View more
2024-09-16
ImmuneOnco and Instil Bio Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, IMM2510/SYN-2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
Dallas, Texas, and Shanghai, China, Sep. 16, 2024 – Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541, “ImmuneOnco”) announced today the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in front-line non-small cell lung cancer (NSCLC) and in front-line triple-negative breast cancer (TNBC).
View more
2024-09-11
Further payment received under the license and collaboration agreement with SynBioTx for IMM2510 and IMM27M
This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the“Company,” together with its subsidiaries, the “Group”) on a voluntary basis to inform shareholders and potential investo
View more
2024-08-22
Upfront payment received under the license and collaboration agreement with SynBioTx for IMM2510 and IMM27M
This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the“Company,” together with its subsidiaries, the “Group”) on a voluntary basis to inform shareholders and potential investo
View more
2024-08-01
ImmuneOnco and Instil Bio Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
Shanghai, China and Dallas, TX, August 01, 2024 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”) and Instil Bio, Inc. (Nasdaq: TIL, “Instil”), today announced a defin
View more
总计 63 1234567891011